Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8748 versus aflibercept in neovascular age-related macular degeneration
2025-524894-17-00Phase 3Authorised
- Sponsor
- EyeBio
- Start
- Jun 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of tiespectus and aflibercept in exudative macular degeneration (3 arms), sponsored by EyeBio. Primary endpoint: Mean change in best-corrected visual acuity letter score from baseline to Year 1. Planned start Jun 2026; status: authorised.
02
Drugs
tiespectusaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2025-524894-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524894-17-00.